Davis Comments on Dealing with Rise in Shareholder Activism
October 30, 2017
Corporate Secretary
Partner Gardner Davis is quoted in a Corporate Secretary article, “Avoiding Checkmate: How Boards Can Prepare For Activists,” about what companies can do to stave off or deal with an activist approach.
Davis said that many public companies go through simulations on how to respond to an activist and have completed related assessments, sometimes hiring outside experts – including activists – to carry out the assessments for them. He also said such assessments should be updated each year to reflect changing conditions at the company itself, changes relative to its peers and changing best practices.
“No directors should get on-the-job training in real time,” he added.
Davis said that many public companies go through simulations on how to respond to an activist and have completed related assessments, sometimes hiring outside experts – including activists – to carry out the assessments for them. He also said such assessments should be updated each year to reflect changing conditions at the company itself, changes relative to its peers and changing best practices.
“No directors should get on-the-job training in real time,” he added.
People
Related News
February 6, 2026
In the News
Louis Lehot Featured for Insights on Evolution of Dealmaking
Foley & Lardner LLP partner Louis Lehot highlighted the evolution of dealmaking in the Silicon Valley Business Journal article, "The Old Playbook Doesn't Work Anymore."
February 6, 2026
In the News
Gregory Husisian on What U.S.-India Trade Deal Means for Fashion Supply Chains
Foley & Lardner LLP Gregory Husisian discussed the broader geopolitical evolution of the US-India agreement in the Vogue Business article, “What the US-India Trade Deal Could Mean for Fashion’s Supply Chains.”
February 2, 2026
In the News
Aaron Maguregui Outlines AI Regulation and Pharma Challenges in Health Care
Foley & Lardner LLP partner Aaron Maguregui examining the regulatory landscape for AI in the health care industry in the PharmaVoice article, “As artificial intelligence increasingly takes on new patient-facing roles, laws lag behind.”